Carbohydrate drugs (Part 2) (iminosugars and rare diseases)
In the part 1 we talked about monosaccharides used for the treatment of common diseases, like influenza or angina
Abstract submission for EuroCD 2019 Deadline extended: 15 June
The 6th European Cyclodextrin Symposium will be held on October 2-4, 2019 in Santiago de Compostela. The main organizer is
Carbohydrate drugs (Part 3) (Disaccharides)
In the previous posts we talked a little bit about monosaccharide type active pharmaceutical ingredients. The next are disaccharides: composed of
CD-enabled natural antimicrobial composition for food
Epolyly ® CD ε-Polylysine + β-Cyclodextrin Epolyly® CD is a natural antimicrobial composition of ε-polylysine and β-Cyclodextrin, effective
BIO International Convention in Philadelphia
BIO 2019 gives opportunity for 16000+ biotechnology and pharma leaders to come together for one week of intensive networking on
Carbohydrate drugs (Part 2) (iminosugars and rare diseases)
In the part 1 we talked about monosaccharides used for the treatment of common diseases, like influenza or angina
Carbohydrate drugs (Part 1)
As we know, cyclodextrins are composed of α-D-glucopyranose units. Among pharmaceuticals there are several other carbohydrate type drugs. In this
The Use of ADV6209 for Premedication in Pediatric Anesthesia
A recently posted phase 2 clinical trial (not yet recruiting) aims to evaluate the effect of ADV6209, a new oral
Axsome Therapeutics Announces Acceleration of MOMENTUM Phase 3 Trial of AXS-07 in Migraine
Axsome Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today
Cyclodextrins as possible antidotes to box jellyfish venom
Box jellyfish (Chironex fleckeri) found in coastal waters from northern Australia and New Guinea north to the Philippines and Vietnam
Enrollment completed of Phase 1 Clinical Trial of Captisol-enabled Iohexol
Ligand Pharmaceuticals Incorporated announced completion of enrollment of the Company’s Phase 1 clinical trial of its internal Captisol-enabled (CE) Iohexol